These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37823484)

  • 1. Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection.
    Straub TJ; Lombardo MJ; Bryant JA; Diao L; Lodise TP; Freedberg DE; Wortman JR; Litcofsky KD; Hasson BR; McGovern BH; Ford CB; Henn MR
    Clin Infect Dis; 2024 Apr; 78(4):833-841. PubMed ID: 37823484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.
    Berenson CS; Lashner B; Korman LY; Hohmann E; Deshpande A; Louie TJ; Sims M; Pardi D; Kraft CS; Wang EEL; Cohen SH; Feuerstadt P; Oneto C; Misra B; Pullman J; De A; Memisoglu A; Lombardi DA; Hasson BR; McGovern BH; von Moltke L; Lee CH
    Clin Infect Dis; 2023 Nov; 77(11):1504-1510. PubMed ID: 37539715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SER-109 (VOWST
    Blair HA
    Drugs; 2024 Mar; 84(3):329-336. PubMed ID: 38441806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SER-109, an Oral Microbiome Therapy for Recurrent
    Feuerstadt P; Louie TJ; Lashner B; Wang EEL; Diao L; Bryant JA; Sims M; Kraft CS; Cohen SH; Berenson CS; Korman LY; Ford CB; Litcofsky KD; Lombardo MJ; Wortman JR; Wu H; Auniņš JG; McChalicher CWJ; Winkler JA; McGovern BH; Trucksis M; Henn MR; von Moltke L
    N Engl J Med; 2022 Jan; 386(3):220-229. PubMed ID: 35045228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A microbial consortium alters intestinal
    Rooney AM; Cochrane K; Fedsin S; Yao S; Anwer S; Dehmiwal S; Hota S; Poutanen S; Allen-Vercoe E; Coburn B;
    mBio; 2023 Aug; 14(4):e0348222. PubMed ID: 37404011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool.
    McChalicher CWJ; Lombardo MJ; Khanna S; McKenzie GJ; Halvorsen EM; Almomani S; Schuster B; Hasson BR; McGovern BH; Ege DS; Auniņš JG
    J Infect Dis; 2023 Nov; 228(10):1452-1455. PubMed ID: 37540090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microbiota restoration therapies for recurrent
    DuPont HL; DuPont AW; Tillotson GS
    Therap Adv Gastroenterol; 2024; 17():17562848241253089. PubMed ID: 38800353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gram-Negative Taxa and Antimicrobial Susceptibility after Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.
    Steed DB; Wang T; Raheja D; Waldman AD; Babiker A; Dhere T; Kraft CS; Woodworth MH
    mSphere; 2020 Oct; 5(5):. PubMed ID: 33055258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on microbiota-derived therapies for recurrent Clostridioides difficile infections.
    Benech N; Barbut F; Fitzpatrick F; Krutova M; Davies K; Druart C; Cordaillat-Simmons M; Heritage J; Guery B; Kuijper E;
    Clin Microbiol Infect; 2024 Apr; 30(4):462-468. PubMed ID: 38101472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depletion of butyrate-producing microbes of the Firmicutes predicts nonresponse to FMT therapy in patients with recurrent
    Tian H; Cui J; Ye C; Zhao J; Yang B; Xu Y; Ji S; Wang L; Lv X; Ma C; Zhou S; Li N; Wang X; Qin H; Chen Q
    Gut Microbes; 2023; 15(1):2236362. PubMed ID: 37469017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
    Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
    Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies.
    Berry P; Khanna S
    BioDrugs; 2023 Nov; 37(6):757-773. PubMed ID: 37493938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study.
    Langdon A; Schwartz DJ; Bulow C; Sun X; Hink T; Reske KA; Jones C; Burnham CD; Dubberke ER; Dantas G;
    Genome Med; 2021 Feb; 13(1):28. PubMed ID: 33593430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.
    McGovern BH; Ford CB; Henn MR; Pardi DS; Khanna S; Hohmann EL; O'Brien EJ; Desjardins CA; Bernardo P; Wortman JR; Lombardo MJ; Litcofsky KD; Winkler JA; McChalicher CWJ; Li SS; Tomlinson AD; Nandakumar M; Cook DN; Pomerantz RJ; Auninš JG; Trucksis M
    Clin Infect Dis; 2021 Jun; 72(12):2132-2140. PubMed ID: 32255488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial.
    Sims MD; Khanna S; Feuerstadt P; Louie TJ; Kelly CR; Huang ES; Hohmann EL; Wang EEL; Oneto C; Cohen SH; Berenson CS; Korman L; Lee C; Lashner B; Kraft CS; Ramesh M; Silverman M; Pardi DS; De A; Memisoglu A; Lombardi DA; Hasson BR; McGovern BH; von Moltke L;
    JAMA Netw Open; 2023 Feb; 6(2):e2255758. PubMed ID: 36780159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and engraftment of new bacterial strains by shotgun metagenomic sequence analysis in patients with recurrent Clostridioides difficile infection before and after fecal microbiota transplantation and in healthy human subjects.
    Verma S; Dutta SK; Firnberg E; Phillips L; Vinayek R; Nair PP
    PLoS One; 2021; 16(7):e0251590. PubMed ID: 34252073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diluted Fecal Community Transplant Restores Clostridioides difficile Colonization Resistance to Antibiotic-Perturbed Murine Communities.
    Lesniak NA; Tomkovich S; Henry A; Taylor A; Colovas J; Bishop L; McBride K; Schloss PD
    mBio; 2022 Aug; 13(4):e0136422. PubMed ID: 35913161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.
    Kraft CS; Sims M; Silverman M; Louie TJ; Feuerstadt P; Huang ES; Khanna S; Berenson CS; Wang EEL; Cohen SH; Korman L; Lee C; Kelly CR; Odio A; Cook PP; Lashner B; Ramesh M; Kumar P; De A; Memisoglu A; Lombardi DA; Hasson BR; McGovern BH; von Moltke L; Pardi DS;
    Infect Dis Ther; 2024 Jun; ():. PubMed ID: 38941068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile Infection following Fecal Microbiota Transplantation.
    Staley C; Kelly CR; Brandt LJ; Khoruts A; Sadowsky MJ
    mBio; 2016 Dec; 7(6):. PubMed ID: 27999162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation.
    Gonzales-Luna AJ; Spinler JK; Oezguen N; Khan MAW; Danhof HA; Endres BT; Alam MJ; Begum K; Lancaster C; Costa GP; Savidge TC; Hurdle JG; Britton R; Garey KW
    Anaerobe; 2021 Aug; 70():102387. PubMed ID: 34044101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.